Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Respiratory Disease Vaccine Market CAGR Analysis And Future Market Development
The market for vaccines targeting respiratory diseases has experienced slight expansion in recent times. Expected to rise from $70.03 billion in 2025 to $71.36 billion in 2026, this represents a compound annual growth rate (CAGR) of 1.9%. This historical growth has been driven by factors such as a high incidence of respiratory infections, restricted access to effective immunizations, government-led vaccination programs, progress in monoclonal antibody development, and increased public consciousness regarding respiratory well-being.
The market for respiratory disease vaccines is anticipated to experience consistent expansion over the coming years, reaching a projected value of $81 billion by 2030, reflecting a compound annual growth rate (CAGR) of 3.2%. This growth during the forecast period is driven by factors such as a rising need for universal vaccines, progress in mRNA and viral vector technologies, improvements in cold-chain logistics, enhanced collaboration between public and private sectors for vaccine delivery, and a stronger emphasis on pandemic readiness and quick response capabilities. Key trends expected to shape this period involve the creation of next-generation respiratory vaccines, a heightened focus on immunization for children and the elderly, the broadening of vaccination initiatives in developing economies, the emergence of combination vaccines offering protection against multiple pathogens, and the implementation of platforms enabling swift vaccine development and distribution.
Download A Free Sample Report For Comprehensive Market Insights:
Respiratory Disease Vaccine Market Industry Drivers: What Is Driving Revenue Growth?
The growing prevalence of tuberculosis (TB) is anticipated to drive expansion in the respiratory disease vaccine market moving forward. TB, an infectious respiratory condition caused by Mycobacterium tuberculosis, predominantly impacts the lungs and poses a major global health challenge. This increase in TB cases stems from weakened healthcare infrastructures, diagnostic delays, and extended transmission patterns, all of which intensify the overall disease load. Respiratory disease vaccines are vital in lowering TB-associated threats by decreasing infection rates, curbing disease spread, and reinforcing international prevention initiatives. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based federal agency, reported a rise in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the escalating incidence of tuberculosis is fueling growth in the respiratory disease vaccine market.
Respiratory Disease Vaccine Market Categorization By Product Type And Application
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine
Respiratory Disease Vaccine Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the respiratory disease vaccine market are focusing their efforts on developing novel products to boost effectiveness and deliver superior options for preventing and managing respiratory disease infections. For example, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, secured approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, designed to prevent lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older. ABRYSVO is an unadjuvanted vaccine composed of two preF proteins engineered to optimize immune response against RSV A and B strains, and it has been clinically demonstrated to be both safe and effective.
Respiratory Disease Vaccine Market Company Landscape And Strategic Competition
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
Access The Complete Respiratory Disease Vaccine Market Report:
Respiratory Disease Vaccine Market Largest Region: Which Geography Holds The Highest Market Share?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model